Ѫ¹ÜÑ×Ö¢·´Ó¦,vascular inflammationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þÑõ»¯Ì¼½áºÏÁ¦,carbon dioxide combining powerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÃÚÄòÉúֳϵͳ¼²²¡/΢ÉúÎïѧ,urogenital diseases/microbiologyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µâ131,iodine l31Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÖÐЧÒȵºËØ,Isophane InsulinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ñÁÐßÁ຿ØÊÍƬ,Glipizide Controlled-Rrelease TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ó¼××´ÏÙËØÄÆƬ,Levothyroxine Sodium TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÆÏÌÑÌǸººÉ,glucose loadÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¡·Ê´ó,muscular hypertrophyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¡ÒòÖÎÁÆ,etiological treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »îÐÔÑõ×ÔÓÉ»ù(ROS),Reactive Oxygen Species (ROS)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éø͸ÐÔÅòÕÍ,osmotic expansionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉöСÇò·Ê´ó,Glomerular hypertrophyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Û·ÉÆ,ShanshanÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ËÀÍö¹Øϵ,Death relationshipÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ñ­»·×æϸ°û,Circulating progenitor cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚƤϸ°û΢¿ÅÁ£,endothelial microparticlesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ϸ°ûÒò×ÓÐźÅתµ¼ÒÖÖÆÒò×Ó3,suppressor of cytokine signaling 3Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÑÛÄÚ×¢Éä,intraocular injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÄò²¡ÖÜΧѪ¹Ü²¡,Diabetic Peripheral Vascular DiseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½Ó´¥ÐÔÈÈÍ´ÓÕ·¢µçλ,Contact heat evoked potentialÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾­½Þ×´Ìåƽ̹²¿²£Á§ÌåÇиîÊõ,pars plana vitrectomyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ë«ÄÜXÏß²âÁ¿,Dual-energy X-ray absorptiometry(DXA)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« RF/6Aϸ°û,RF/6A cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒȵºËØÆô¶¯×Ó,Insulin promoterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·À¿ØÍøÂç,prevention and control networkÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« AT_4ÊÜÌå,AT_4 receptorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ô¤»ìÒȵºËØ,premixed insulinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« CDK11p58»ùÒò,CDK11p58 geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« È˼××´ÅÔÏÙ¼¤ËØ(1-34)Ƭ¶Î,Human parathyroid hormone(1-34) fragmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉöÉÏÏÙƤÖʹ¦ÄܼõÍË,adrenocortical insufficiencyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²Ç°ÆÚ,Preclinical phaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« СÏËάÉñ¾­²¡,Small Fiber neuropathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ßÒȵºËØ-ÕýѪÌÇǯ¼Ð,hyperinsulinemic-euglycemic clampÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶¨Á¿CT²â¶¨·¨,Quantitative Computed TomographyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Èⶾ¼îÖ¬õ£×ªÒÆø1,Acyl-CoA oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹«°²¼à¹Ü³¡Ëù,the public security supervision and management areasÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶à·¢ÐÔ¼¡Ñ×Ñù×ÛºÏÕ÷,polymyositis-like syndromeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« NADPÑõ»¯Ã¸,NADPH oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼××´ÏÙËØ/ÖÎÁÆÓ¦ÓÃ,thyroxine/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÇÖÊÊèËÉÐÔ×µÌåѹËõ¹ÇÕÛ,osteoporotic vertebral compressive fractureÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« С×éÖÎÁÆ,Group interventionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇ´úлָ±ê,Metabolic indicesÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¦Âϸ°ûµòÍö,¦Â-cell apoptosisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »úеʹãÐ,Mechanical thresholdÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÚƤϸ°ûÒ»Ñõ»¯µªºÏø,Endothelial nitric oxide synthaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÛÏ´¼¿¹Ñõ»¯Îï(ø),thiol antioxidantsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ±Ç¾Ò¼Ùµ¥°û¾ú,Pseudomonas malleiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÄò²¡Ç°ÆÚ״̬,Prediabetic stateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »¹Ô­ÐÍÑÌõ£°·ÏÙàÑßʶþºËÜÕËáÁ×ËáÑõ»¯Ã¸,Nicotinamide adenine dinucleotide phosphate oxidaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼××´ÏÙ²¡,thyroid diseaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÏÂÖ«´óѪ¹Ü²¡±ä,Macroangiopathy of lower limbÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 2ÐÍÌÇÄò²¡ÊÓÍøĤ²¡±ä,type 2 diabetic retinopathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö¬·¾ËáºÏ³Éø(FAS),fatty acid synthase(FAS)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉÏÊкóÆÀ¼Û,post-marketed evaluationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ½µÑªÌÇÒ©/ÖÎÁÆÓ¦ÓÃ,Hypoglycemic Agents/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ç⻯´ó¶¹Á×Ö¬,hydrogenated soybean phosphatidylcholineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿Õ¸¹Ìǵ÷½ÚÊÜËð,Impaired fasting glucoseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ÇÂå,William Edgar GeilÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ðļ¡¼äÖÊÖع¹,myocardial interstitial remodelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÄò²¡¿ØÖÆÇé¿ö,Quality in evaluating diabetes controlÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ѫ֬ÐÔ×´,blood-fat traitÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¿Ú·þ½µÌÇÒ©Îï,Oral hypoglycemic agentsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¼¡´¼¼ÓÑõø,myoinositol oxygenaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¥ÏòÇíÖ¬À©É¢,single immunodiffusion testÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« É£Òø½µÌǽºÄÒ,Sangyin capsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ê¿×¼õѹÊõ,drilling decompressionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂýÐÔ˯Ãß°þ¶á,Chronic sleep deprivationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µÍѪÌÇÉú³ÉÖ¸Êý,low glycemic-indexÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¹ÀËã·¨,estimation methodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¨¹Ì´¼ºÏ³ÉÒÖÖƼÁ,cholesterol-synthesizing inhabitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÄÔ¸ÉÌý¾õÓÕ·¢µçλÂý³É·Ö,slow component of brainstem auditory evoked potentialsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÂýÐÔ¼ÙÐÔ³¦¹£×è,Chronic intestinal pseudo-obstructionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²¹Éö½¡Æ¢ÖÐÒ©,Chinese herbs for reinforcing Shen and strenghening PiÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÄò²¡ÔçÆÚÉöËðÉË,Early diabetic kidney injury Urinary microalbuminuriaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÒÆÖ²ºóÌÇÄò²¡,post-transplantation diabetes mellitusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÄò²¡×ã/Ò©ÎïÁÆ·¨,diabetic foot/drug therapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Éú³¤¼¤ËشٷÖÃÚËØÊÜÌå-1a»ùÒò,growth hormone secretagogue receptor-1a geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Áúµ¨Ðº¸ÎƬ,Longdan Xiegan TabletsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ß·¢ÆÚ,the highest periodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÉöÉÏÏÙƤÖʹ¦ÄܼõÍËÖ¢,adrenal hypofunctionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ç°Áеضû(¿­Ê±),Liop PGE1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¾ø¾­ÄêÏÞ,menopausal periodÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 2ÐÍÌÇÄò²¡ÔçÆÚÉö²¡,type 2 diabetes and early signs of nephropathyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Ö¬ÁªËØÊÜÌå-1,adiponectin receptor-1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÄò²¡²¡»ú,diabetes mellitus pathogenesisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »ìºÏÐÔ¸ß֬Ѫ֢,Compound hyperlipimiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« 7-¶þ·úÑǼ׻ù-5,4'-¶þ¼×ÍéÑõ»ùÒì»Æͪ,7-Difluoromethylyl-5,4'-Di-methoxyl isoflavoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÌÇÄò²¡Éö²¡»¼Õß,Diabetic nephropathy patientÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÈÑÉïÆÚÌÇ´úлÒì³£,gestational abnormal glucose metabolismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« HBV¸ÐȾģʽ,HBV infection typeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« µ¥²à̽²é,Unilateral explorationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ÁÙ´²ÕïÖηÖÎö,analysis of clinical managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ·ÇÊÖÊõ·½·¨,Nonsurgical techniqueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ²ÍºóÔ˶¯,postprandial exerciseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« »îѪ½µÌǽºÄÒ,Huoxuejiangtang CapsuleÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ×ÌÒõÈóÔï·¨,method of nourishing yin and moistering aridÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« Õ³¸½¹¦ÄÜ,adhesive functionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¸ßÒȵºËØ-ÕýÆÏÌÑÌÇǯ¼Ð¼¼Êõ,hyperinsulinemic-euglycemic clampÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ« ¶þÌÇ×é³É,disaccharide compositionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
 ÉÏÒ»Ò³ 1 2 3 4 5 6 7 8 ÉÏÒ»Ò³